# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia

> **NCT01114126** · PHASE1 · COMPLETED · sponsor: **Neurim Pharmaceuticals Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** Neu-P11
- **DRUG:** Neu-P11 placebo

## Key facts

- **NCT ID:** NCT01114126
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-02
- **Final completion:** 2011-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2011-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114126, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01114126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*